- Home
- SRFM vs TENX Comparison
SRFM vs TENX Comparison
Compare SRFM & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | TENX |
|---|---|---|
| Founded | 2011 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.7M | 56.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRFM | TENX |
|---|---|---|
| Price | $1.97 | $11.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.81 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 3.0M | 157.3K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $108,158,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.77 | $4.63 |
| 52 Week High | $9.91 | $10.65 |
Technical Indicators
Market Signals| Indicator | SRFM | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 77.78 |
| Support Level | $2.18 | $9.40 |
| Resistance Level | $2.38 | $10.55 |
| Average True Range (ATR) | 0.19 | 0.60 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 8.99 | 88.46 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.